Minimal Residual Disease Testing Heads Toward USD 7.2 Billion as Liquid Biopsy and Sequencing Reshape Cancer Monitoring

Minimal Residual Disease Market is expanding as oncologists look for earlier and more precise ways to detect cancer cells that remain after treatment. According to Polaris Market Research, the industry was valued at USD 2.38 billion in 2025 and is estimated at USD 2.69 billion in 2026. It is projected to reach USD 7.20 billion by 2034, registering a CAGR of 13.1% from 2026 to 2034. Rising cancer incidence, precision medicine, and advances in sequencing are making residual disease testing a standard part of modern cancer care.

Cancer Burden and Precision Medicine Drive Demand

Growing cancer incidence and patient numbers are creating steady demand for tools that can show whether treatment has worked and whether relapse risk remains. Precision medicine adds to this need, since therapy decisions increasingly depend on molecular information rather than imaging or clinical signs alone. Higher research and development spending, along with discussions at the US FDA Oncologic Drugs Advisory Committee on residual disease as a trial endpoint, are strengthening the clinical and regulatory case for testing.

Sequencing and Liquid Biopsy Open New Opportunities

Next-generation sequencing is central to the shift. A better regulatory and reimbursement environment for sequencing-based diagnostics, together with cloud computing and genome mapping programs, is helping laboratories run more sensitive assays at scale. Liquid biopsy and circulating tumor DNA testing allow repeated monitoring from a simple blood sample, which suits long-term surveillance. Polaris also points to expansion into solid tumors such as lung, breast, and colorectal cancer, and to growing use in clinical trials and drug development, as major opportunities for the Minimal Residual Disease Market.

AI, Cell Therapy, and Transplant Monitoring

Artificial intelligence is being applied to speed up data analysis, improve result interpretation, predict relapse risk, and automate laboratory work, though the report describes these benefits qualitatively. Testing is also growing in CAR-T and immunotherapy monitoring, stem cell transplant follow-up, and precision oncology programs, where clinicians need to track response closely.

Restraints to Watch

Cost is a key barrier, with assays priced from USD 500 to over USD 3,000 and serial testing adding to expense. A lack of standardized procedures means results can vary by institution and equipment, and limited insurance reimbursement slows adoption. Providers that improve standardization and demonstrate clinical value to payers are likely to gain an advantage.

Segment Highlights

By detection target, leukemia held the largest share at 38.6% in 2025. Solid tumors are expected to grow fastest at a 15.4% CAGR from 2026 to 2034, followed by lymphoma at 13.8% and multiple myeloma at 12.9%.

By technique, flow cytometry led with a 34.8% share in 2025. Next-generation sequencing is projected to expand at a 16.2% CAGR, while PCR is expected to grow at 12.6%.

By end user, hospitals and specialty clinics accounted for 50.6% of the market in 2025, reflecting their role in patient care and treatment monitoring. Laboratory centers are expected to grow at a 14.7% CAGR as testing outsources and specialized labs scale.

Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market

Regional Outlook

North America was the largest region in 2025 with a 45.7% share, supported by a strong clinical and research infrastructure and wide adoption of advanced diagnostics across the United States and Canada. Asia Pacific is the fastest-growing major region at a 15.2% CAGR, with India projected at 16.8%. Europe is expected to grow at 12.4%, Latin America at 12.2%, and the Middle East and Africa at 11.6%.

Competitive Landscape

Key players include Adaptive Biotechnologies, ArcherDX, ARUP Laboratories, Asuragen, Bio-Rad Laboratories, Cergentis, F. Hoffmann-La Roche, Genetron Health, GRAIL, Guardant Health, ICON plc (MolecularMD), Inivata, Invivoscribe, Mission Bio, Natera, NeoGenomics Laboratories, OPKO Health, QIAGEN, Quest Diagnostics, and Sysmex Corporation.

Recent activity shows how competitive the field has become. In December 2025, Natera agreed to acquire Foresight Diagnostics for USD 450 million. In May 2026, Illumina launched a distributed whole-genome sequencing solution for residual disease research. In June 2026, Quest Diagnostics’ Haystack MRD circulating tumor DNA test was approved in New York. In September 2026, Natera’s Signatera received Japanese approval as a companion diagnostic in muscle-invasive bladder cancer. Earlier, in January 2025, Adaptive Biotechnologies and NeoGenomics announced a partnership on blood cancer monitoring.

Minimal Residual Disease Market growth will depend on how quickly testing moves from specialist centers into routine practice. With sequencing costs falling, solid tumor applications expanding, and regulators showing more interest in residual disease endpoints, demand should remain strong through 2034. Companies that deliver standardized, well-reimbursed tests with clear clinical value will be best placed to lead the next phase of growth.

More Trending Latest Reports By Polaris Market Research:

Feed Acidifiers Market

Photovoltaic Materials Market

Composite Packaging Market

North America Veterinary Clinical Trials Market

Photovoltaic Materials Market

Fructooligosaccharides Market

Air Starter Market

3D Motion Capture System Market

Benign Prostatic Hyperplasia Surgical Treatment Market